Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00358215 · ClinicalTrials.gov registry record · Phase 3
RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
A Phase 3 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 3
- Development phase
- 2,278
- Enrollment target
NCT00358215: Completed Phase 3 study, sponsored by Amgen.
NCT00358215 is a Phase 3 study that has completed, run by Amgen. The registered enrollment target is 2,278 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (195% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00358215, a Phase 3 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 2,278 participants
- Enrollment target
Study Summary
The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemia.
Primary Outcome
Time to death from any cause or first hospital admission for worsening heart failure (adjudicated by the Clinical Endpoint Committee), whichever occurred first, estimated by Kaplan-Meier method. Participants not experiencing a qualifying event during the study were censored at their last contact time or the study termination date, whichever occurred first.
Interventions
- DRUG Placebo
- DRUG Darbepoetin alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,278 participants |
| Start Date | 2006-06-01 |
| Est. Completion | 2012-10-11 |
| Phase | Phase 3 |
What the finished NCT00358215 record still lists
NCT00358215 is an interventional study that assigns participants to a tested intervention. Its 2,278 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (195% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00358215 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00358215 about?
NCT00358215 is a clinical study titled "RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial". The purpose of the study is to determine the efficacy of treatment of anemia with darbepoetin alfa compared to placebo on the composite of time to death from any cause or first hospital admission for worsening heart failure in patients with symptomatic left ventricular systolic dysfunction and anemi...
What is the current status of trial NCT00358215?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 2,278 participants. The study started on 2006-06-01. Estimated completion is 2012-10-11.
What interventions are being tested in trial NCT00358215?
The interventions under investigation include: Placebo (DRUG), Darbepoetin alfa (DRUG).
Who is sponsoring clinical trial NCT00358215?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00358215's enrollment target sits among peer trials
2,278 94th of 2000 higher than 1,907 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03968393 · 2,270 participants · Phase 4
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
- NCT05530343 · 2,298 participants · NA
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
- NCT04124120 · 2,300 participants · NA
Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women
- NCT05237258 · 2,300 participants · NA
Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI